KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Investments: 2014-2023

Historic Long-Term Investments for Pacira BioSciences (PCRX) over the last 8 years, with Dec 2023 value amounting to $2.4 million.

  • Pacira BioSciences' Long-Term Investments fell 93.52% to $2.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.4 million, marking a year-over-year decrease of 93.52%. This contributed to the annual value of $2.4 million for FY2023, which is 93.52% down from last year.
  • Per Pacira BioSciences' latest filing, its Long-Term Investments stood at $2.4 million for FY2023, which was down 93.52% from $37.2 million recorded in FY2022.
  • Pacira BioSciences' 5-year Long-Term Investments high stood at $95.5 million for FY2020, and its period low was $2.4 million during FY2023.
  • Its 2-year average for Long-Term Investments is $19.8 million, with a median of $19.8 million in 2022.
  • As far as peak fluctuations go, Pacira BioSciences' Long-Term Investments skyrocketed by 150.47% in 2019, and later tumbled by 93.52% in 2023.
  • Pacira BioSciences' Long-Term Investments (Yearly) stood at $64.8 million in 2019, then spiked by 47.32% to $95.5 million in 2020, then reached $37.2 million in 2022, then plummeted by 93.52% to $2.4 million in 2023.